NASDAQ: MREOMereo Biopharma Group PLC Stock
$0.57+0.08 (+16.33%)
Updated Jan 12, 2026
MREO Price
$0.57
Fair Value Price
N/A
Market Cap
$90.23M
52 Week Low
$0.20
52 Week High
$3.39
P/E
-1.89x
P/B
1.94x
P/S
658.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$500.00k
Earnings
-$41.57M
Gross Margin
73.6%
Operating Margin
-8,583.6%
Profit Margin
-8,314.6%
Debt to Equity
0.15
Operating Cash Flow
-$33M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MREO Overview
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MREO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MREO
Ranked#316 of 491
Ranked#316 of 491
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.78 | A | |
| $6.00 | A | |
| $163.68 | A |
Be the first to know about important MREO news, forecast changes, insider trades & much more!
MREO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MREO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MREO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MREO is good value based on its book value relative to its share price (1.94x), compared to the US Biotechnology industry average (5.46x)
P/B vs Industry Valuation
MREO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MREO due diligence checks available for Premium users.
Valuation
MREO fair value
Fair Value of MREO stock based on Discounted Cash Flow (DCF)
Price
$0.57
Fair Value
$2.14
Undervalued by
73.39%
MREO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MREO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.89x
Industry
169.02x
Market
45.03x
MREO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
5.46x
MREO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MREO's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.0M
Profit Margin
0%
MREO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MREO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.6M
Liabilities
$7.0M
Debt to equity
0.15
MREO's short-term assets ($52.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MREO's short-term assets ($52.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MREO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.3M
Investing
$300.0k
Financing
$0.0
MREO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MREO vs Biotech Stocks
Mereo Biopharma Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.